ECTRIMS 2017

Aubagio may cause delays in conversion to clinical definite MS by slowing the loss of cortical grey matter.

Patients experienced reduced disease activity when switched to alemtuzumab.

Data show superiority of OCREVUS compared to Rebif in reducing disability progression independent of relapse activity in people with RMS.

Celgene announced new Phase 3 data evaluating the safety and efficacy of ozanimod vs Avonex for RMS.

An emerging line of inquiry suggests a potential association between comorbidities and MS relapses, but studies have been limited.

Researchers believe that environmental factors may impact disease severity characteristics in genetically susceptible populations.

With its 20-minute application time, the BICAMS is one of the few tools available for small centers with only a few staff members who might not be trained in administering neuropsychological tests.